XML 34 R13.htm IDEA: XBRL DOCUMENT v3.22.4
Investments and fair value measurements
12 Months Ended
Dec. 31, 2022
Fair Value Disclosures [Abstract]  
Investments and fair value measurements
4. Investments and fair value measurements

The Company’s assets and liabilities that are measured at fair value on a recurring or nonrecurring basis within the fair value hierarchy are as follows (in thousands):

As of December 31, 2022
Level 1Level 2Level 3
Cash equivalents:
Money market funds$130,377 $— $— 
U.S. government securities— 48,900 — 
Total cash equivalents$130,377 $48,900 $— 
Marketable securities:
U.S. government securities$— $151,687 $— 
Non-current assets:
Strategic investments$— $— $12,104 
Non-current liabilities:
Cash settled stock appreciation rights$— $— $462 
As of December 31, 2021
Level 1Level 2Level 3
Non-current assets:
Strategic investments$— $— $10,000 
Non-current liabilities:
Cash settled stock appreciation rights$— $— $818 

A summary of the changes in the fair value of Level 3 financial instruments, of which remeasurement of SARs, remeasurement of redeemable convertible preferred stock warrants, and strategic investment impairment are recognized in the consolidated statements of operations, is as follows (in thousands):

WarrantsStock Appreciation RightsStrategic Investments
Balance— December 31, 2019
$108 $36 $— 
Change in fair value of redeemable convertible preferred stock warrants52 — — 
Vesting and remeasurement of SARs, net— 232 — 
Balance— December 31, 2020
160 268 — 
Exercise of redeemable convertible preferred stock warrants(160)— — 
Vesting and remeasurement of SARs, net— 550— 
Purchases of strategic investments— — 10,000 
Balance— December 31, 2021
— 818 10,000 
Vesting and remeasurement of SARs, net— (294)— 
Purchases of strategic investments— — 5,000 
Amount reclassified from liability to equity upon exchange— (62)— 
Unrealized loss on strategic investments— — (2,896)
Balance— December 31, 2022
$— $462 $12,104 

During the fiscal year ended December 31, 2021, the remaining outstanding 12,595 warrants to purchase Series A-1 redeemable convertible preferred stock were exercised for an immaterial amount of cash proceeds at an exercise price of $0.196 per share. The Company reclassified the $0.2 million fair value of the warrants into Series A-1 redeemable convertible preferred stock on the consolidated balance sheet. The change in fair value of the warrants during fiscal year ended December 31, 2021 was immaterial.